Antihypertensive drug treatment and circadian blood pressure rhythm: A review of the role of chronotherapy in hypertension

Current Pharmaceutical Design

Volumn 21, Issue 6, 2015, Pages 756-772

  Schillaci, Giuseppe ^a,b   Battista, Francesca ^a,b   Settimi, Laura ^a   Schillaci, Luca ^a   Pucci, Giacomo ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Azienda Ospedaliero Universitaria di Terni   (Italy)

Author keywords

Chronotherapy; Dipping; Hypertension; Nocturnal blood pressure; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BEDTIME DOSAGE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONOTHERAPY; CIRCADIAN RHYTHM; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DOSAGE SCHEDULE COMPARISON; EVENING DOSAGE; HUMAN; HYPERTENSION; LONG TERM CARE; MEDICATION COMPLIANCE; MORBIDITY; MORNING DOSAGE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SLEEP; SLEEP QUALITY; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHRONOTHERAPY; CIRCADIAN RHYTHM; HUMANS; HYPERTENSION;

EID: 84925875229     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141024130013     Document Type: Article

References (115)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-2260. Erratum in: Lancet 2013; 381: 1276. Lancet 2013; 381: 628.
2. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120: 1598-605.
3. Khatib R, Schwalm JD, Yusuf S, et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLOS One 2014; 9: e84238.
4. Taddei S, Bruno RM, Ghiadoni L. The correct administration of antihypertensive drugs according to the principles of clinical pharmacology. Am J Cardiovasc Drugs 2011; 11: 13-20.
5. Hermida RC, Ayala DE, Fernández JR, et al. Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int 2013; 30: 280-314.
6. Hermida RC, Ayala DE, Mojón A, Fernández JR. Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am J Hypertens 2012; 25: 325-34.
7. Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F. Administration-time-dependent effects of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press Monit 2010; 15: 173-80.
8. Richardson DW, Honour AJ, Goodman AC. Changes in arterial pressure during sleep in man. Hypertension 1968; 16: 62-78.
9. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers [letter]. Lancet 1988; 2: 397.
10. Kario K, Shimada K. Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens 2004; 26: 177-89.
11. Metoki H, Ohkubo T, Kikuya M, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension 2006; 47: 149-54.
12. Bursztyn M, Mekler J, Wachtel N, Ben-Ishay D. Siesta and ambulatory blood pressure monitoring. Comparability of the afternoon nap and night sleep. Am J Hypertens 1994; 7: 217-21.
13. Perk G, Ben-Arie L, Mekler J, Bursztyn M. Dipping status may be determined by nocturnal urination. Hypertension 2001; 37: 749-52.
14. Schillaci G, Verdecchia P, Borgioni C, et al. Predictors of diurnal blood pressure changes in 2042 subjects with essential hypertension. J Hypertens 1996; 14: 1167-73.
15. Anan F, Takahashi N, Ooie T, Yufu K, Saikawa T, Yoshimatsu H. Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res 2003; 26: 669-76.
16. Lurbe A, Redón J, Pascual JM, Tacons J, Alvarez V, Batlle DC. Altered blood pressure during sleep in normotensive subjects with type I diabetes. Hypertension 1993; 21: 227-35.
17. Seeman T, Palyzová D, Dusek J, Janda J. Reduced nocturnal blood pressure dip and sustained nighttime hypertension are specific markers of secondary hypertension. J Pediatr 2005; 147: 366-71.
18. Mann S, Craig MW, Melville DI, Balasubramanian V, Raftery EB. Physical activity and the circadian rhythm of blood pressure. Clin Sci 1979; 57(suppl 5): 291S-4S.
19. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, Reboldi G. Hypertension 2007; 49: 777-83. Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation.
20. Nagata K, Osada N, Shimazaki M, et al. Diurnal blood pressure variation in patients with sleep apnea syndrome. Hypertens Res 2008; 31: 185-91.
21. Verdecchia P, Schillaci G, Borgioni C, et al. Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension. J Hypertens 1995; 13: 1209-15.
22. Agyemang C, Bhopal R, Bruijnzeels M, Redekop WK. Does nocturnal blood pressure fall in people of African and South Asian descent differ from that in European white populations? A systematic review and meta-analysis. J Hypertens 2005; 23: 913-20.
23. Cardoso CR, Leite NC, Freitas L, Dias SB, Muxfeld ES, Salles GF. Pattern of 24-hour ambulatory blood pressure monitoring in type 2 diabetic patients with cardiovascular dysautonomy. Hypertens Res 2008; 31: 865-72.
24. Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G. Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1997; 96: 1859-62.
25. Uzu T, Kazembe FS, Ishikawa K, Nakamura S, Inenaga T, Kimura G. High sodium sensitivity implicates nocturnal hypertension in essential hypertension. Hypertension 1996; 28: 139-42.
26. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-36.
27. Verdecchia P, Schillaci G, Borgioni C, et al. Gender, day-night blood pressure changes and left ventricular mass in essential hypertension: dippers and peakers. Am J Hypertens 1995; 8: 193-6.
28. Schmieder RE, Rockstroh JK, Aepfelbacher F, Schulze B, Messerli FH. Gender-specific cardiovascular adaptation due to circadian blood pressure variations in essential hypertension. Am J Hypertens 1995; 8: 1160-6.
29. Cuspidi C, Macca G, Sampieri L, et al. Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J Hypertens 2001; 19: 1539-5.
30. Marinakis AG, Vyssoulis GP, Michaelides AP, Karpanou EA, Cokkinos DV, Toutouzas PK. Impact of abnormal nocturnal blood pressure fall on vascular function. Am J Hypertens 2003; 16: 209-13.
31. Parati G. Blood pressure reduction at night: sleep and beyond. J Hypertens 2000; 18: 1725-9.
32. Schillaci G, Verdecchia P, Zampi I, Battistelli M, Bartoccini C, Porcellati C. Non-invasive ambulatory BP monitoring during the night: randomised comparison of different reading intervals. J Hum Hypertens 1994; 8: 23-7.
33. Omboni S, Parati G, Palatini P, et al. Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study (Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation). J Hypertens 1998; 16: 733-8.
34. Mochizuki Y, Okutani M, Donfeng Y, et al. Limited reproducibility of circadian variation in blood pressure dippers and nondippers. Am J Hypertens 1998; 11: 403-9.
35. Verdecchia P, Angeli F, Reboldi G. Optimizing the definition of dippers and nondippers: is a 70-86% full glass empty? J Hypertens 2008; 26: 630-2.
36. Henskens LH, Kroon AA, van Oostenbrugge RJ, Haest RJ, Lodder J, de Leeuw PW. Different classifications of nocturnal blood pressure dipping affect the prevalence of dippers and nondippers and the relation with target-organ damage. J Hypertens 2008; 26: 691-8.
37. van Ittersum FJ, Ijzerman RG, Stehouwer CDA, Donker AJM. Analysis of twenty-four-hour ambulatory blood pressure monitoring: what time period to assess blood pressures during waking and sleeping? J Hypertens 1995; 13: 1053-8.
38. Fagard R, Brguljan J, Thijs L, Staessen J. Prediction of the actual awake and asleep blood pressures by various methods of 24 h pressure analysis. J Hypertens 1996; 14: 557-63.
39. Weston PJ, Robinson JE, Watt PA, Thurston H. Reproducibility of the circadian blood pressure fall at night in healthy young volunteers. J Hum Hypertens 1996; 10: 163-6.
40. Degaute J-P, van de Borne P, Kerkhofs M, Dramaix M, Linkowski P. Does non-invasive blood pressure monitoring disturb sleep? J Hypertens 1992; 10: 879-85.
41. Kammila S, Campbell NR, Brant R, deJong R, Culleton B; University of Calgary Clinical Hypertension Research Group. Systematic error in the determination of nocturnal blood pressure dipping status by ambulatory blood pressure monitoring. Blood Press Monit 2002, 7: 131-4.
42. Mojón A, López JE. Relationship between physical activity and blood pressure in dipper and non-dipper hypertensive patients. J Hypertens 2002, 20: 1097-104.
43. Cavelaars M, Tulen JH, Manin't Veld AJ, Gelsema ES, van den Meiracker AH. Assessment of body position to quantify its effect on nocturnal blood pressure under ambulatory conditions. J Hypertens 2000; 18: 1737-43.
44. Ben-Dov IZ, Ben-Arieh L, Mekler J, Bursztyn M. Blood pressure dipping is reproducible in clinical practice. Blood Press Monit 2005; 10: 79-84.
45. Chaves H, Campello de Souza FM, Krieger EM. The reproducibility of dipping status: beyond the cutoff points. Blood Press Monit 2005; 10: 201-5.
46. O'Brien E, Parati G, Stergiou G, et al; European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31: 1731-68. Erratum in: J Hypertens 2013; 31: 2467.
47. Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.
48. Schillaci G, Battista F, Pucci G. Nocturnal blood pressure dipping: systolic, diastolic, or both? J Hypertens 2014; 32: 699-700.
49. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008; 51: 55-61.
50. Verdecchia P, Schillaci G, Borgioni C, et al. Altered circadian blood pressure profile and prognosis. Blood Press Monit 1997; 2: 347-52.
51. Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 2002; 20: 2183-9.
52. Hoshide S, Kario K, Hoshide Y, et al. Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens 2003; 16: 434-8.
53. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46: 156-61.
54. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47: 846-53.
55. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801. Erratum in: Hypertension 1995; 25: 462.
56. Staessen JA, Thijs L, Fagard R, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282: 539-46.
57. Yamamoto Y, Akiguchi I, Oiwa K, Hayashi M, Kimura J. Adverse effect of nighttime blood pressure on the outcome of lacunar infarct patients. Stroke 1998; 29: 570-6.
58. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-6.
59. Li Y, Thijs L, Hansen TW, et al. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension 2010; 55: 1040-8.
60. Verdecchia P, Angeli F, Mazzotta G, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension 2012; 60: 34-42.
61. Kario K, Shimada K. Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens 2004; 26: 177-89.
62. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension 2011; 57: 3-10.
63. O’Brien E. 24-h ambulatory blood pressure measurement in clinical practice and research: a critical review of a technique in need of implementation. J Intern Med 2011; 269: 478-95.
64. Palatini P. Non-dipping in hypertension: still a challenging problem. J Hypertens 2004; 22: 2269-72.
65. Cappuccio FP, Cooper D, D’Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J 2011; 32: 1484-9.
66. Leenen FH, Coletta E. Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension. J Cardiovasc Pharmacol 2010; 56: 669-75.
67. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-20.
68. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764. Erratum in: Lancet 1997; 350: 1636.
69. Black HR, Elliott WJ, Grandits G, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003; 289: 2073-82.
70. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53. Erratum in: N Engl J Med 2000; 342: 1376. N Engl J Med 2000; 342: 748.
71. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38: e28-e32.
72. Dolan E, Stanton AV, Thom S, et al. ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients—an Anglo-Scandinavian Cardiac Outcomes Trial substudy. J Hypertens 2009; 27: 876-85.
73. Zhao P, Xu P, Wan C, Wang Z. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev 2011; 10: CD004184.
74. Acelajado MC, Pisoni R, Dudenbostel T, Oparil S, Calhoun DA, Glasser SP. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hypertens 2012; 6: 66-72.
75. Asmar R, Gosse P, Queré S, Achouba A. Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. Blood Press Monit 2011; 16: 80-6.
76. Calvo C, Hermida RC, Ayala DE, et al. Chronotherapy with torasemide in hypertensive patients: increased efficacy and therapeutic coverage with bedtime administration. Med Clin 2006; 127: 721-9.
77. Glasser SP, Neutel JM, Gana TJ, Albert KS. Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension. Am J Hypertens 2003; 16: 51-8.
78. Hermida RC, Calvo C, Ayala DE, et al. Administration timedependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 2003; 42: 283-90.
79. Hermida RC, Calvo C, Ayala DE, et al. Administration-timedependent effects of doxazosin gits on ambulatory blood pressure of hypertensive subjects. Chronobiol Int 2004; 21: 277-96.
80. Hermida RC, Calvo C, Ayala DE, et al. Administration timedependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol Int 2005; 22: 755-76.
81. Hermida RC, Calvo C, Ayala DE, et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 2005; 23: 1913-22.
82. Hermida RC, Calvo C, Ayala DE, et al. Dose-and administration time-dependent effects of nifedipine gits on ambulatory blood pressure in hypertensive subjects. Chronobiol Int 2007; 24: 471-93.
83. Hermida RC, Ayala DE, Fernandez JR, Calvo C. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 2007; 50: 715-22.
84. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Am J Hypertens 2008; 21: 948-54.
85. Hermida RC, Ayala DE, Mojon A, et al. Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int 2008; 25: 950-70.
86. Hermida RC, Ayala DE, Chayan L, Mojon A, Fernandez JR. Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol Int 2009; 26: 61-79.
87. Hermida RC, Ayala DE. Chronotherapy with the angiotensinconverting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 2009; 54: 40-6.
88. Hermida RC, Ayala DE, Mojon A, Alonso I, Fernandez JR. Reduction of morning blood pressure surge after treatment with nifedipine GITS at bedtime, but not upon awakening, in essential hypertension. Blood Press Monit 2009; 14: 152-9.
89. Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Chronobiol Int 2010; 27: 1287-303.
90. Hermida RC, Ayala DE, Mojón A, Fontao MJ, Fernández JR. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol Int 2011; 28: 601-10.
91. Meng Y, Zhang Z, Liang X, Wu C, Qi G. Effects of combination therapy with amlodipine and fosinopril administered at different times on blood pressure and circadian blood pressure pattern in patients with essential hypertension. Acta Cardiol 2010; 65: 309-14.
92. Morgan T, Anderson A, Jones E. The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J Hypertens 1997; 15: 205-11.
93. Myburgh DP, Verho M, Botes JH, Erasmus TP, Luus HG 24-hour blood pressure control with ramipril: comparison of once-daily morning and evening administration. Curr Ther Res Clin Exp 1995; 56: 1298-306.
94. Neutel JM, Rotenberg K. Comparison of a chronotherapeutically administered beta blocker vs. a traditionally administered beta blocker in patients with hypertension. J Clin Hypertens 2005; 7: 395-400.
95. Nold G, Strobel G, Lemmer B. Morning versus evening amlodipine treatment: effect on circadian blood pressure profile in essential hypertensive patients. Blood Press Monit 1998; 3: 17-25.
96. Palatini P. Can an angiotensin-converting enzyme inhibitor with a short half-life effectively lower blood pressure for 24 hours?. Am Heart J 1992; 123: 1421-5.
97. Pechère-Bertschi A, Nussberger J, Decosterd L, et al. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 1998; 16: 385-93.
98. Qiu YG, Chen JZ, Zhu JH, Yao XY. Differential effects of morning or evening dosing of amlodipine on circadian blood pressure and heart rate. Cardiovasc Drugs Ther 2003; 17: 335-41.
99. Rahman M, Greene T, Phillips RA, et al. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension 2013; 61: 82-8.
100. [100] Tofé Povedano S, García De LaVilla B. 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens (Greenwich) 2009; 11: 426-31.
101. [101] Wang C, Zhang J, Liu X, et al. Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern. J Clin Hypertens (Greenwich) 2013; 15: 48-54.
102. [102] White WB, Mansoor GA, Pickering TG, et al. Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate. Am J Hypertens 1999; 12: 806-14.
103. [103] Zeng J, Jia M, Ran H, et al. Fixed-combination of amlodipine and diuretic chronotherapy in the treatment of essential hypertension: improved blood pressure control with bedtime dosing-a multicenter, open-label randomized study. Hypertens Res 2011; 34: 767-72.
104. [104] Hoshino A, Nakamura T, Matsubara H. The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy. Clin Exp Hypertens 2010; 32: 416-22.
105. [105] Kario K, Hoshide S, Shimizu M, et al. Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J Hypertens 2010; 28: 1574-83.
106. [106] Hermida RC, Calvo C, Ayala DE, López JE. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 2005; 46: 960-8.
107. [107] Suzuki K, Aizawa Y. Evaluation of dosing time-related antihypertensive efficacy of valsartan in patients with type 2 diabetes. Clin Exp Hypertens 2011; 33: 56-62.
108. [108] Mori H, Yamamoto H, Ukai H, et al; COMPATIBLE Study Group. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study. Hypertens Res 2013; 36: 202-7.
109. [109] Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010; 27: 1629-51.
110. [110] Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 2011; 34: 1270-6.
111. [111] Hermida RC, Ayala DE, Mojón A, Fernández JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22: 2313-2221.
112. [112] Hermida RC, Ayala DE, Mojón A, Fernández JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol 2011; 58: 1165-73.
113. [113] Suzuki M, Kimura Y, Tsushima M, Haranop Y. Association of insulin resistance with salt sensitivity and nocturnal fall in blood pressure. Hypertension 2000; 35: 864-8.
114. [114] American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1: S11-66.
115. [115] Carter BL, Chrischilles EA, Rosenthal G, Gryzlak BM, Eisenstein EL, Vander Weg MW. Efficacy and safety of nighttime dosing of antihypertensives: review of the literature and design of a pragmatic clinical trial. J Clin Hypertens (Greenwich) 2014; 16: 115-21.